A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Cholangiocarcinoma; Glioblastoma; Glioma; Solid tumours
- Focus Therapeutic Use
- 19 Jul 2018 Planned End Date changed from 31 Jul 2018 to 31 Jul 2019.
- 19 Jul 2018 Planned primary completion date changed from 31 Jul 2018 to 31 Jul 2019.
- 12 Jun 2018 Status changed from recruiting to suspended.